Takeda Pharmaceutical (TAK) Total Current Liabilities (2017 - 2026)

Takeda Pharmaceutical has reported Total Current Liabilities for 10 years, with the latest figure at $6.2 billion in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 79.2% year-over-year to $6.2 billion in Q2 2026; TTM through Jun 2026 was $6.2 billion, a 79.2% increase from a year earlier, with the FY2026 full-year figure at $6.4 billion, up 76.68% from the prior year.
• Total Current Liabilities was $6.2 billion for Q2 2026 at Takeda Pharmaceutical, down from $6.4 billion in the prior quarter.
• The five-year high for Total Current Liabilities was $6.4 billion in Q1 2026, with the low at $3.3 billion in Q4 2023.
• Average Total Current Liabilities over 5 years is $4.0 billion, with a median of $3.8 billion recorded in 2025.
• The sharpest annual moves came in 2022 and 2026: Total Current Liabilities slipped 14.29% in 2022, then surged 79.2% in 2026.
• Over 5 years, Total Current Liabilities stood at $3.3 billion in 2022, then slipped by 2.55% to $3.3 billion in 2023, then gained by 13.14% to $3.7 billion in 2024, then gained by 2.61% to $3.8 billion in 2025, then surged by 64.75% to $6.2 billion in 2026.
• The last three Total Current Liabilities figures came in at $6.2 billion (Q2 2026), $6.4 billion (Q1 2026), and $3.8 billion (Q4 2025), per Business Quant data.